Showing 329 results
July 2020
-
Media ReleaseSandoz announces plans for joint investment to help strengthen future of antibiotics manufacturing in EuropeSandoz and Austrian government announce joint plans to drive long-term competitiveness of European production for key antibiotics in Europe Planned combined investment of more than EUR 150 million…
-
Media ReleaseNovartis delivered strong H1 performance. FY 2020 guidance confirmed at higher end for core operating income and lower end for sales.Due to COVID-19 first half results are more representative of underlying performance than Q2, sales growth of 6% (cc1, +3% USD) and core¹ operating income growth of 19% (cc, +14% USD): Innovative…
-
Media ReleaseSandoz launches generic antibiotic Daptomycin in US, strategically growing injectables portfolio and strengthening hospital offeringDaptomycin is an antibacterial medicine used to treat adult patients with complicated skin and skin structure infections 1 Daptomycin can be used to treat patients with MRSA or “superbug”…
-
Media ReleaseSandoz collaborates with Civica Rx to help reduce critical generic medicine shortages in US hospitalsSandoz to provide six injectable medicines used in acute care settings to help ensure supply reliability for optimal patient care Securing reliable supply of and access to these high-quality…
-
Media ReleaseSandoz reviewing options after Federal Circuit upholds lower court ruling in biosimilar Erelzi® caseSandoz evaluating next steps, including potential appeal to US Supreme Court Ruling continues to prevent launch of important, affordable treatment option for US patients affected by chronic…
June 2020
-
Media ReleaseNovartis discontinues hydroxychloroquine clinical trial based on slow enrollment, remains committed to pandemic research effortsStudy discontinued due to feasibility of recruitment; no safety issues have been reported or efficacy conclusions made Novartis remains committed to ongoing research and development for COVID-19…
-
Media ReleaseSandoz launches once-daily generic tacrolimus for transplant patients in EuropeSandoz is first and only company offering complete range of dosing options in several European markets*, with 2 mg capsule allowing for fine dose titration Sandoz 2 mg slow-release capsule offers…
April 2020
-
Media ReleaseNovartis maintains strong operational performance in Q1, confirms FY 2020 guidance at this time, and advances a broad range of efforts to support the global response to COVID-19Q1 2020 net sales from continuing operations1 grew 13% (cc2, +11% USD) with double digit growth (cc) in Innovative Medicines and Sandoz: Key growth drivers include Entresto USD 569 million (+62% cc…
-
Media ReleaseNovartis to sponsor large clinical trial of hydroxychloroquine in hospitalized COVID-19 patientsNovartis has reached an agreement with the US Food and Drug Administration (FDA) to proceed with a Phase III clinical trial of hydroxychloroquine in hospitalized patients with COVID-19 disease Trial…
-
Media ReleaseNovartis announces mutual agreement to terminate sale of Sandoz US generic oral solids, dermatology portfolio to AurobindoBasel, April 1, 2020 – Novartis today announced the mutual agreement with Aurobindo Pharma USA Inc. to terminate the agreement to sell the Sandoz US generic oral solids and dermatology businesses to…